Biologically active peloids as monotherapy in patients with chronic abacterial prostatitis

Abstract

BACKGROUND: Chronic prostatitis is the most prevalent condition among male reproductive system disorders. The treatment of chronic prostatitis has not only medical but also significant social implications.

AIM: To evaluate the efficacy of a biogenic complex containing Tambukan mud in patients with chronic abacterial prostatitis.

MATERIALS AND METHODS: The study included 67 patients aged 28 to 57 years diagnosed with chronic abacterial prostatitis. All patients received a biogenic complex containing Tambukan mud in the form of suppositories, administered twice daily for 15 days. The total follow-up period was 1 month, with clinical evaluations conducted during the initial visit, on Day 15 (second visit), and on Day 30 (third visit).

RESULTS: Analysis of patient-reported outcomes using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) revealed that the total score decreased from 25.9 ± 3.8 to 3.9 ± 0.11 during treatment. Palpation of the prostate gland showed improvement: in all 67 patients (100%), the prostate became elastic, and in 63 patients (94%), it became non-tender. Transrectal ultrasound findings at the second visit demonstrated an average prostate volume reduction of 1.3 times, which further decreased to 1.5 times by the third visit. At the third visit, there was a statistically significant increase in both peak systolic and diastolic blood flow velocities in the central and peripheral zones of the prostate compared to baseline (p < 0.001).

CONCLUSIONS: The findings indicate that a biogenic complex containing Tambukan mud has a beneficial effect on the key clinical manifestations of chronic abacterial prostatitis. It significantly reduces pain and urinary symptoms, decreases prostate volume, restores prostatic hemodynamics, and may be recommended for this patient population.

Keywords

chronic abacterial prostatitis / peloid therapy / biologically active peloids / Tambukan mud

References

[1] Alyaev YuG, Glybochko PV, Pushkar DYu, editors. Urology: Russian clinical guidelines. Moscow: GEOTAR-Media; 2018. 480 p. (In Russ.)

[2] Урология: российские клинические рекомендации // под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. Москва: ГЭОТАР-Медиа, 2018. 480 с.

[3] Kogan MI, Naboka YuL, Ismailov RS. Prostatic secretion microbiota: a comparative analysis of the сhronical prostatitis II and IIIA category. Urologiia. 2020;(2):16–22 EDN: JFPPAL doi: 10.18565/urology.2020.2.16-22

[4] Коган М.И., Набока Ю.Л., Исмаилов Р.С. Микробиота секрета простаты: сравнительный анализ хронического простатита категорий II и IIIA // Урология. 2020. № 2. С. 16–22. EDN: JFPPAL doi: 10.18565/urology.2020.2.16-22

[5] Kulchavenya EV, Brijatuk EV, Kholtobin DP, Cherednichenko AG. Current approach to diagnosis of chronic prostatitis. Urologiia. 2021;(2):32–39 EDN: EPOUNB doi: 10.18565/urology.2021.2.32-39

[6] Кульчавеня Е.В., Брижатюк Е.В., Холтобин Д.П., Чередниченко А.Г. Современный подход к диагностике хронического простатита // Урология. 2021. № 2. С. 32–39. EDN: EPOUNB doi: 10.18565/urology.2021.2.32-39

[7] Tyuzikov IA, Grekov EA. Chronic prostatitis/chronic pelvic pain syndrome: current trends and prospects for treatment from the standpoint of evidence-based medicine. Experimental and Clinical Urology. 2022;15(1):90–100. EDN: WGJAHU doi: 10.29188/2222-8543-2022-15-1-90-100

[8] Тюзиков И.А., Греков Е.А. Хронический простатит/синдром хронической тазовой боли: современные тренды и перспективы лечения с позиций доказательной медицины // Экспериментальная и клиническая урология. 2022. Т. 15, № 1. С. 90–100. EDN: WGJAHU doi: 10.29188/2222-8543-2022-15-1-90-100

[9] Vinnik YuYu, Kuzmenko AV, Amelchenko AA. Modern concepts about chronic prostate inflammation. Urology Reports (St. Petersburg). 2022;12(4):333–345. EDN: HYSEOP doi: 10.17816/uroved111902

[10] Винник Ю.Ю., Кузьменко А.В., Амельченко А.А. Современные представления о хроническом воспалении простаты // Урологические ведомости. 2022. Т. 12, № 4. C. 333–345. EDN: HYSEOP doi: 10.17816/uroved111902

[11] Zhang J, Liang C, Shang X, Li H. Chronic prostatitis/chronic pelvic pain syndrome: a disease or symptom? current perspectives on diagnosis, treatment, and prognosis. Am J Mens Health. 2020;14(1):1557988320903200. doi: 10.1177/1557988320903200

[12] Zhang J., Liang C., Shang X., Li H. Chronic prostatitis/chronic pelvic pain syndrome: a disease or symptom? current perspectives on diagnosis, treatment, and prognosis // Am J Mens Health. 2020. Vol. 14, N 1. P. 1557988320903200. doi: 10.1177/1557988320903200

[13] Segal AS. Diseases of the male genital system. Moscow: ICAR; 2010. 324 p. (In Russ.)

[14] Сегал А.С. Заболевания половой системы мужчин. Москва: ИКАР, 2010. 324 c.

[15] Tsukanov AYu, Rudchenko NV, Mozgovoy SI, Maslyukov AV. Protection of the prostate in conditions of chronic pelvis varicose. Urologiia. 2021;(4):53–60. EDN: XGJIBQ doi: 10.18565/urology.2021.4.53-60

[16] Цуканов А.Ю., Мозговой С.И., Рудченко Н.В., Маслюков А.В. Органопротекция предстательной железы в условиях варикозного расширения вен малого таза // Урология. 2021. № 4. С. 56–60. EDN: XGJIBQ doi: 10.18565/urology.2021.4.53-60

[17] Zhang Y, Ma H, Nan T, et al. Comparative efficacy of oral Chinese patent medicine for chronic prostatitis/chronic pelvic pain syndrome with sexual dysfunction: a Bayesian network meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:649470. doi: 10.3389/fphar.2021.649470

[18] Zhang Y., Ma H., Nan T., et al. Comparative efficacy of oral Chinese patent medicine for chronic prostatitis/chronic pelvic pain syndrome with sexual dysfunction: a Bayesian network meta-analysis of randomized controlled trials // Front Pharmacol. 2021. Vol. 12. P. 649470. doi: 10.3389/fphar.2021.649470

[19] Kulchovenya EV, Neymark AI. Prostatit. 2nd ed. Moscow: GEOTAR-Media; 2022. 248 p. (In Russ.) EDN: BRZRIS

[20] Кульчавеня Е.В., Неймарк А.И. Простатит. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2022. 248 c. EDN: BRZRIS

[21] van Reijn-Baggen DA, Han-Geurts IJM, Voorham-van der Zalm PJ, et al. Pelvic floor physical therapy for pelvic floor hypertonicity: a systematic review of treatment efficacy. Sex Med Rev. 2022;10(2):209–230. doi: 10.1016/j.sxmr.2021.03.002

[22] van Reijn-Baggen D.A., Han-Geurts I.J.M., Voorham-van der Zalm P.J., et al. Pelvic floor physical therapy for pelvic floor hypertonicity: a systematic review of treatment efficacy // Sex Med Rev. 2022. Vol. 10, N 2. P. 209–230. doi: 10.1016/j.sxmr.2021.03.002

[23] Vinnik YuYu, Kuzmenko AV, Gyaurgiev TA. Treatment of the chronic prostatitis: current state of the problem. Urologiia. 2021;(4): 138–144 EDN: IBPWGQ doi: 10.18565/urology.2021.4.138-144

[24] Винник Ю.Ю., Кузьменко А.В., Гяургиев Т.А. Лечение хронического простатита: современное состояние проблемы // Урология. 2021. № 4. С. 138–144. EDN: IBPWGQ doi: 10.18565/urology.2021.4.138-144

[25] Franco JVA, Turk T, Jung JH, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2020;125(4):490–496. doi: 10.1111/bju.14988

[26] Franco J.V.A., Turk T., Jung J.H., et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review // BJU Int. 2020. Vol. 125, N 4. P. 490–496. doi: 10.1111/bju.14988

[27] Evdokimov VV. Pharmacotherapy of acute and chronic prostatitis. Difficult patient. 2010;8(6–7):40–43. (In Russ.) EDN: OGBOEP

[28] Евдокимов В.В. Фармакотерапия острого и хронического простатита // Трудный пациент. 2010. Т. 8, № 6–7. С. 40–43. EDN: OGBOEP

[29] Tyuzikov IA. Chronic prostatitis as a neuro-endocrine syndrome and new potential pharmacotherapeutical options for managing of the problem. Pharmacology & Pharmacotherapy. 2021;(1):58–66. EDN: AJYKRE doi: 10.46393/2713-2129_2021_1_58-66

[30] Тюзиков И.А. Хронический простатит как нейроэндокринный синдром и новые потенциальные фармакотерапевтические опции управления проблемой // Фармакология & Фармакотерапия. 2021. № 1. С. 58–66 EDN: AJYKRE doi: 10.46393/2713-2129_2021_1_58-66

[31] Peng X, Gao H, Wang J. Cryotherapy alleviates symptoms in chronic prostatitis/chronic pelvic pain syndrome: The first results. Andrologia. 2021;53(2):e13920. doi: 10.1111/and.13920

[32] Peng X., Gao H., Wang J. Cryotherapy alleviates symptoms in chronic prostatitis/chronic pelvic pain syndrome: The first results // Andrologia. 2021. Vol. 53, N 2. P. e13920. doi: 10.1111/and.13920

[33] Efimenko NV, Menshikova TB, Vasin VA, et al. Therapeutic muds of lake Bolshoy Tambukan in rehabilitation of socially significant diseases. Resort Medicine. 2015;(2):89–94. EDN: ZVWFPI

[34] Ефименко Н.В., Меньшикова Т.Б., Васин В.А., и др. Лечебные грязи озера Большой Тамбукан в медицинской реабилитации социально значимых заболеваний // Курортная медицина. 2015. № 2. С. 89–94. EDN: ZVWFPI

[35] Magri V, Boltri M, Cai T, et al. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;90(4):227–248. doi: 10.4081/aiua.2018.4.227

[36] Magri V., Boltri M., Cai T., et al. Multidisciplinary approach to prostatitis // Arch Ital Urol Androl. 2019. Vol. 90, N 4. P. 227–248. doi: 10.4081/aiua.2018.4.227

[37] Vinarov АZ. Modern view on etiology, pathogenesis and treatment of chronic pelvic pain syndrome. Urologiia. 2017;1:114–122. EDN: YJAMIB doi: 10.18565/urol.2017.1.114-122

[38] Винаров А.З. Современные представления об этиологии, патогенезе и лечении синдрома хронической тазовой боли // Урология. 2017. № 1. С. 114–122. EDN: YJAMIB doi: 10.18565/urol.2017.1.114-122

RIGHTS & PERMISSIONS

Eco-Vector